362 related articles for article (PubMed ID: 32539460)
21. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
[TBL] [Abstract][Full Text] [Related]
22. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
[TBL] [Abstract][Full Text] [Related]
23. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
[TBL] [Abstract][Full Text] [Related]
24. Mortality and Sudden Cardiac Death Risk Stratification Using the Noninvasive Combination of Wide QRS Duration and Late Gadolinium Enhancement in Idiopathic Dilated Cardiomyopathy.
Marume K; Noguchi T; Tateishi E; Morita Y; Kamakura T; Ishibashi K; Noda T; Miura H; Nishimura K; Nakai M; Yamada N; Tsujita K; Anzai T; Kusano K; Ogawa H; Yasuda S
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e006233. PubMed ID: 29654132
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Magnetic Resonance to Predict Appropriate Implantable Cardioverter Defibrillator Therapy in Ischemic and Nonischemic Cardiomyopathy Patients Using Late Gadolinium Enhancement Border Zone: Comparison of Four Analysis Methods.
Jablonowski R; Chaudhry U; van der Pals J; Engblom H; Arheden H; Heiberg E; Wu KC; Borgquist R; Carlsson M
Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28838961
[TBL] [Abstract][Full Text] [Related]
26. High-resolution three-dimensional late gadolinium-enhanced cardiac magnetic resonance imaging to identify the underlying substrate of ventricular arrhythmia.
Hennig A; Salel M; Sacher F; Camaioni C; Sridi S; Denis A; Montaudon M; Laurent F; Jais P; Cochet H
Europace; 2018 Sep; 20(FI2):f179-f191. PubMed ID: 29069369
[TBL] [Abstract][Full Text] [Related]
27. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
[TBL] [Abstract][Full Text] [Related]
28. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in hypertrophic cardiomyopathy in children: An MRI based study.
Ali LA; Marrone C; Martins DS; Khraiche D; Festa P; Martini N; Santoro G; Todiere G; Panaioli E; Bonnet D; Boddaert N; Aquaro GD; Raimondi F
Int J Cardiol; 2022 Oct; 364():141-147. PubMed ID: 35718011
[TBL] [Abstract][Full Text] [Related]
30. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance.
Caetano F; Botelho A; Trigo J; Silva J; Almeida I; Venâncio M; Pais J; Sanches C; Leitão Marques A
Rev Port Cardiol; 2014 May; 33(5):261-7. PubMed ID: 24909443
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
[TBL] [Abstract][Full Text] [Related]
33. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy.
Hanneman K; Crean AM; Williams L; Moshonov H; James S; Jiménez-Juan L; Gruner C; Sparrow P; Rakowski H; Nguyen ET
J Thorac Imaging; 2014 Nov; 29(6):331-9. PubMed ID: 25314027
[TBL] [Abstract][Full Text] [Related]
34. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.
Greulich S; Deluigi CC; Gloekler S; Wahl A; Zürn C; Kramer U; Nothnagel D; Bültel H; Schumm J; Grün S; Ong P; Wagner A; Schneider S; Nassenstein K; Gawaz M; Sechtem U; Bruder O; Mahrholdt H
JACC Cardiovasc Imaging; 2013 Apr; 6(4):501-11. PubMed ID: 23498675
[TBL] [Abstract][Full Text] [Related]
35. Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy.
Di Marco A; Brown PF; Bradley J; Nucifora G; Claver E; de Frutos F; Dallaglio PD; Comin-Colet J; Anguera I; Miller CA; Schmitt M
J Am Coll Cardiol; 2021 Jun; 77(23):2890-2905. PubMed ID: 34112317
[TBL] [Abstract][Full Text] [Related]
36. Incremental significance of myocardial oedema for prognosis in hypertrophic cardiomyopathy.
Xu Z; Wang J; Cheng W; Wan K; Li W; Pu L; Xu Y; Sun J; Han Y; Chen Y
Eur Heart J Cardiovasc Imaging; 2023 Jun; 24(7):876-884. PubMed ID: 37073085
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of CMR in patients presenting with ventricular arrhythmias.
Dawson DK; Hawlisch K; Prescott G; Roussin I; Di Pietro E; Deac M; Wong J; Frenneaux MP; Pennell DJ; Prasad SK
JACC Cardiovasc Imaging; 2013 Mar; 6(3):335-44. PubMed ID: 23433931
[TBL] [Abstract][Full Text] [Related]
38. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
[TBL] [Abstract][Full Text] [Related]
39. Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement.
Halliday BP; Baksi AJ; Gulati A; Ali A; Newsome S; Izgi C; Arzanauskaite M; Lota A; Tayal U; Vassiliou VS; Gregson J; Alpendurada F; Frenneaux MP; Cook SA; Cleland JGF; Pennell DJ; Prasad SK
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1645-1655. PubMed ID: 30219397
[TBL] [Abstract][Full Text] [Related]
40. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S
Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
